Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 20c
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Join SI Premium – FREE
Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q1 EPS of ($0.14), $0.20 better than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- FTI Consulting names Jerome Nyssen senior managing director in Australia
- Western Midstream prices $700M in senior notes due 2036
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
